Navigation Links
Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
Date:7/22/2009

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Orexigen expects to grant to the underwriter a 30-day option to purchase up to an additional 1,350,000 shares of common stock to cover overallotments, if any. All of the shares are being offered by Orexigen. Leerink Swann LLC is acting as sole book-running manager for the offering.

The securities described above are being offered by Orexigen pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. When available, copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave(R), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Prime Therapeutics Receives TIPPS Certification
7. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
8. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
9. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
10. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
11. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable ... that visits to the dentist fit into their patients’ busy lifestyles. Dental365 also ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... By ... earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ... the top 1% of all charities reviewed by Charity Navigator and earns ANRF a ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/13/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... Food and Drug Administration (FDA) has notified the Company that ... Zhejiang, China manufacturing facility has been ... clearance of the Warning Letter related to our ... of the progress we have made in our ongoing quality ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: